Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive advanced NSCLC | ESMO
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial - The Lancet Oncology
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression | BMC Cancer | Full Text
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer - Clinical Lung Cancer
Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data | Future Oncology
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer | NEJM
Alectinib Replaces Crizotinib Drug as Potential Therapy for Advanced Lung Cancer
Ensartinib Tops Crizotinib in ALK-Positive NSCLC | MedPage Today
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial - Journal of Thoracic Oncology
Crizotinib resistance: implications for therapeutic strategies - Annals of Oncology
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
Trials Highlight Changing Lung Cancer Treatment Landscape - NCI
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L) - Lung Cancer
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology
First-Line ALK+ mNSCLC Clinical Trial - ALECENSA® (alectinib)
Post-Crizotinib Treatment ALK+ mNSCLC Clinical Trials - ALECENSA® (alectinib)
Crizotinib - Wikipedia
Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Crizotinib produces improved OS and PFS in EML4-ALK lung cancer... | Download Scientific Diagram
Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls - ScienceDirect
